Effective 2026-03-15, Cigna classifies oxymetazoline (Rhofade) as not medically necessary when used to treat persistent (nontransient) facial erythema associated with rosacea and lists it under Conditions Not Covered. The policy explains this is consistent with a broader cosmetic-exclusion: treatments intended to correct the cosmetic sequelae of rosacea (e.g., erythema, telangiectasia) are considered cosmetic and not covered. The update acknowledges the FDA indication and AARS guidance noting topical alpha‑agonists can reduce erythema quickly, but clarifies that such pharmacologic treatment for persistent erythema remains excluded from coverage. Providers should not expect coverage for Rhofade when prescribed solely for persistent rosacea-related erythema.
2026-03-15 Revision: `Rhofade (oxymetazoline)` Classified as Not Medically Necessary
This revision clarifies coverage determination for oxymetazoline (Rhofade) as not medically necessary when used for persistent (nontransient) facial erythema associated with rosacea. The policy explicitly lists Oxymetazoline (Rhofade) under "Conditions Not Covered," reinforcing that treatment of persistent erythema with this topical alpha-adrenergic agonist is not a covered benefit under the plan.
The document also reiterates the broader plan position that treatments aimed at correcting the "untoward cosmetic effects" of rosacea (for example: telangiectasia, erythema) are considered cosmetic and not medically necessary. This places Rhofade within a cosmetic exclusion framework rather than as a medically necessary therapeutic option for rosacea-related erythema.
Overview of `Rhofade` Indication and Limitation
The policy defines the clinical indication for Rhofade in the overview: it is an alpha1A-adrenergic agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. The overview also notes a limitation of the indication: Rhofade is not indicated to treat the inflammatory lesions of rosacea.
By presenting both the FDA-indicated use and the indication limitation, the policy establishes the specific clinical context in which Rhofade is intended to act (persistent erythema) while separating it from treatment of papulopustular or other inflammatory rosacea manifestations.
Coverage Rationale: Cosmetic Exclusion Applied to Rosacea Erythema
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.